Literature DB >> 9210355

Prognostic factors in pancreatic carcinoma.

C C Compton1, S J Mulvihill.   

Abstract

Pancreatic cancer is a relatively common malignancy. Its gravity is underscored by the low overall cure rates. A number of clinical, pathologic, and molecular factors have been identified that predict survival of patients with this neoplasm. These factors are reviewed and analyzed.

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9210355

Source DB:  PubMed          Journal:  Surg Oncol Clin N Am        ISSN： 1055-3207            Impact factor:   3.495


  8 in total

1.  Serum platelet factor 4 is an independent predictor of survival and venous thromboembolism in patients with pancreatic adenocarcinoma.

Authors:  Katherine E Poruk; Matthew A Firpo; Luke M Huerter; Courtney L Scaife; Lyska L Emerson; Kenneth M Boucher; Kimberly A Jones; Sean J Mulvihill
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-08-20       Impact factor: 4.254

2.  Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.

Authors:  Jim Zhong; Kirtesh Patel; Jeffrey Switchenko; Richard J Cassidy; William A Hall; Theresa Gillespie; Pretesh R Patel; David Kooby; Jerome Landry
Journal:  Cancer       Date:  2017-05-10       Impact factor: 6.860

Review 3.  Screening for pancreatic cancer: why, how, and who?

Authors:  Katherine E Poruk; Matthew A Firpo; Douglas G Adler; Sean J Mulvihill
Journal:  Ann Surg       Date:  2013-01       Impact factor: 12.969

Review 4.  Early detection of pancreatic cancer.

Authors:  Victoria M Kim; Nita Ahuja
Journal:  Chin J Cancer Res       Date:  2015-08       Impact factor: 5.087

5.  Serum IGFBP2 and MSLN as diagnostic and prognostic biomarkers for pancreatic cancer.

Authors:  Zachary W Kendrick; Matthew A Firpo; Robert C Repko; Courtney L Scaife; Douglas G Adler; Kenneth M Boucher; Sean J Mulvihill
Journal:  HPB (Oxford)       Date:  2013-12-06       Impact factor: 3.647

6.  Heparanase expression is a prognostic indicator for postoperative survival in pancreatic adenocarcinoma.

Authors:  J Rohloff; J Zinke; K Schoppmeyer; A Tannapfel; H Witzigmann; J Mössner; C Wittekind; K Caca
Journal:  Br J Cancer       Date:  2002-04-22       Impact factor: 7.640

7.  Metabolomics based predictive classifier for early detection of pancreatic ductal adenocarcinoma.

Authors:  Keith Unger; Khyati Y Mehta; Prabhjit Kaur; Yiwen Wang; Smrithi S Menon; Shreyans K Jain; Rose A Moonjelly; Shubhankar Suman; Kamal Datta; Rajbir Singh; Paul Fogel; Amrita K Cheema
Journal:  Oncotarget       Date:  2018-05-01

8.  Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies.

Authors:  Victoria M Kim; Alex B Blair; Peter Lauer; Kelly Foley; Xu Che; Kevin Soares; Tao Xia; Stephen T Muth; Jennifer Kleponis; Todd D Armstrong; Christopher L Wolfgang; Elizabeth M Jaffee; Dirk Brockstedt; Lei Zheng
Journal:  J Immunother Cancer       Date:  2019-05-22       Impact factor: 13.751
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.